

OCT 17 2005

Form TO-1595 (Rev 03/05)
USPTO No. 0651-0027 (exp. 6/30/2005)

10-25-2005

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

103105977

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Ambit Biosciences Corporation

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) October 6, 2005

- ☐ Assignment ☐ Merger
- ☒ Security Agreement ☐ Change of Name
- ☐ Joint Research Agreement
- ☐ Government Interest Assignment
- ☐ Executive Order 9424, Confirmatory License
- ☐ Other _____

2. Name and address of receiving party(ies)

Name: Horizon Technology Funding Company LLC

Internal Address: _____

Street Address: 76 Batterson Park RoadCity: FarmingtonState: ConnecticutCountry: USA Zip: 06032Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

A. Patent Application No.(s)

NONE

☐ This document is being filed together with a new application.

B. Patent No.(s)

See attached.

Additional numbers attached? ☒ Yes ☐ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: John C. BombaraInternal Address: Horizon Technology Funding Company
LLCStreet Address: 76 Batterson Park RoadCity: FarmingtonState: Connecticut Zip: 06032Phone Number: 860-676-8657Fax Number: 860-676-8655Email Address: jay@horizontechfinance.com6. Total number of applications and patents involved: 347. Total fee (37 CFR 1.21(h) & 3.41) \$ 1,360.00

- ☐ Authorized to be charged by credit card
- ☐ Authorized to be charged to deposit account
- ☒ Enclosed
- ☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number _____

Authorized User Name _____

9. Signature: _____

Signature

October 12 2005
Date

10/24/2005 DBYRNE 00000113 09653668

01 FC:8021

John C. Bombara

1360100-00 of Person Signing

Total number of pages including cover sheet, attachments, and documents: ☐Documents to be recorded (including cover sheet) should be faxed to (703) 306-5996, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

700244080

PATENT
REEL: 017261 FRAME: 0630



SCHEDULE 1-A TO GRANT OF SECURITY INTEREST

PATENTS

None

SCHEDULE 1-B TO GRANT OF SECURITY INTEREST

PATENT APPLICATIONS

| Patent Application | Owner | Application Number | Filing Date |
|--|-------------------|--------------------|-------------|
| Method to identify gene function using small molecule probe | Ambit Biosciences | 09/653,668 | 09/01/00 |
| Phage display affinity filter and forward screen | Ambit Biosciences | 10/115,442 | 04/02/02 |
| Phage display affinity and specificity filters and forward screen | Ambit Biosciences | 10/406,797 | 04/02/03 |
| Assays and kits for detecting protein binding | Ambit Biosciences | 10/873,835 | 06/21/04 |
| Uncoupling of DNA insert propagation and expression of protein for phage display | Ambit Biosciences | 10/214,654 | 08/07/02 |
| Treatment of Diseases with Kinase Inhibitors | Ambit Biosciences | 10/894,877 | 7/19/04 |
| Compounds and uses thereof | Ambit Biosciences | 10/848,515 | 5/17/04 |
| Heterocyclic compounds and uses thereof | Ambit Biosciences | 10/848,521 | 5/17/04 |
| Heterocyclic compounds and uses thereof | Ambit Biosciences | 10/847,897 | 5/17/04 |
| Pyrrole compounds and uses thereof | Ambit Biosciences | 10/848,584 | 5/17/04 |
| Pyrrole compounds and the treatment of diseases | Ambit Biosciences | 10/989,995 | 11/15/04 |
| Kinase inhibitor and their use in the treatment of disease | Ambit Biosciences | 60/602,584 | 8/18/04 |
| Kinase inhibitor and their use in the treatment of disease | Ambit Biosciences | 60/602,586 | 8/18/04 |
| Kinase inhibitor and their use in the treatment of disease | Ambit Biosciences | 60/602,460 | 8/18/04 |
| Gene targeting by hybridization-hydrolysis | Ambit Biosciences | 11/057,031 | 02/10/05 |

| | | | |
|--|-------------------|------------|----------|
| process | | | |
| Conjugated small molecules | Ambit Biosciences | 11/031,638 | 01/07/05 |
| Urea derivatives as kinase modulators | Ambit Biosciences | 10/989,824 | 11/15/04 |
| Amide derivative as kinase modulators | Ambit Biosciences | 10/989,623 | 11/15/04 |
| Amide derivative as FLT-3 modulators | Ambit Biosciences | 10/989,766 | 11/15/04 |
| Urea derivatives as FLT-3 modulators | Ambit Biosciences | 10/989,717 | 11/15/04 |
| Amide derivatives as C-kit modulators | Ambit Biosciences | 10/990,007 | 11/15/04 |
| Urea derivatives as C-kit modulators | Ambit Biosciences | 10/990,195 | 11/15/04 |
| Amide derivatives as PDGFR modulators | Ambit Biosciences | 10/989,823 | 11/15/04 |
| Urea derivatives as PDGFR modulators | Ambit Biosciences | 10/990,194 | 11/15/04 |
| Amide derivatives as ABL modulators | Ambit Biosciences | 10/989,745 | 11/15/04 |
| Urea derivatives as ABL modulators | Ambit Biosciences | 10/989,814 | 11/15/04 |
| Treatment of Diseases with Kinase Inhibitors | Ambit Biosciences | 60/664,097 | 3/21/05 |
| Pyrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | Ambit Biosciences | 11/035,940 | 1/13/05 |
| Pyrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | Ambit Biosciences | 11/035,939 | 1/13/05 |
| Pyrolopyrimidine derivatives and analogs and their use in the treatment and prevention of disease | Ambit Biosciences | 11/035,619 | 1/13/05 |
| Pyrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | Ambit Biosciences | 11/036,241 | 1/13/05 |
| Kinase inhibitor and uses thereof | Ambit Biosciences | 60/652,197 | 2/11/05 |
| Compounds | Ambit Biosciences | 60/671,409 | 4/13/05 |
| Improved compounds | Ambit Biosciences | 60/671,306 | 4/13/05 |

GRANT OF SECURITY INTEREST
PATENTS

THIS GRANT OF SECURITY INTEREST, dated as of October 6, 2005, is executed by AMBIT BIOSCIENCES CORPORATION, a Delaware corporation with an address of 4215 Sorrento Valley Blvd., San Diego, California 92121 ("Debtor"), in favor of HORIZON TECHNOLOGY FUNDING COMPANY LLC, a Delaware limited liability company with an address of 76 Batterson Park Road, Farmington, Connecticut 06032 ("Secured Party").

A. Pursuant to a certain Venture Loan and Security Agreement, dated on or about the date hereof (the "Agreement") by and between Debtor and the Secured Party, the Secured Party has agreed to extend credit to Debtor upon the terms and subject to the conditions set forth therein;

B. Debtor owns the patents and/or applications for patents, more particularly described on Schedules 1-A and 1-B annexed hereto as part hereof (collectively, the "Patents");

C. Pursuant to the Agreement, Debtor has granted to Secured Party a security interest in all right, title and interest of Debtor in and to the Patents, together with any reissue, continuation, continuation-in-part or extension thereof, and all proceeds thereof, including any and all causes of action which may exist by reason of infringement thereof for the full term of the Patents (the "Collateral"), to secure the prompt payment, performance and observance of the Obligations (as defined in the Agreement);

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Debtor does hereby further grant to Secured Party a security interest in the Collateral to secure the prompt payment, performance and observance of the Obligations.

Debtor does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest in the Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

IN WITNESS WHEREOF, Debtor has caused this instrument to be executed as of the day and year first written above.

AMBIT BIOSCIENCES CORPORATION

By: 
Name: M. SCOTT SALVA
Title: CEO